Brandão Pedro, López Óscar, Leitzbach Luisa, Stark Holger, Fernández-Bolaños José G, Burke Anthony J, Pineiro Marta
University of Coimbra, CQC and Department of Chemistry, 3004-535 Coimbra, Portugal.
LAQV-REQUIMTE, Rua Romão Ramalho, 59, University of Évora, 7000 Évora, Portugal.
ACS Med Chem Lett. 2021 Jul 23;12(11):1718-1725. doi: 10.1021/acsmedchemlett.1c00344. eCollection 2021 Nov 11.
Molecular hybridization is a valuable approach in drug discovery. Combining it with multicomponent reactions is highly desirable, since structurally diverse libraries can be attained efficiently in an eco-friendly manner. In this work, isatin is used as the key building block for the Ugi 4-center 3-component reaction synthesis of oxindole-lactam hybrids, under catalyst-free conditions. The resulting oxindole-β-lactam and oxindole-γ-lactam hybrids were evaluated for their potential to inhibit relevant central nervous system targets, namely cholinesterases and monoamine oxidases. Druglikeness evaluation was also performed, and compounds and exhibited great potential as selective butyrylcholinesterase inhibitors, at the low micromolar range, with an interesting predictive pharmacokinetic profile. Our findings herein reported suggest oxindole-lactam hybrids as new potential agents for the treatment of Alzheimer's disease.
分子杂交是药物发现中的一种重要方法。将其与多组分反应相结合是非常可取的,因为可以以环保的方式高效地获得结构多样的文库。在这项工作中,异吲哚酮在无催化剂条件下用作通过Ugi 4中心3组分反应合成羟吲哚-内酰胺杂化物的关键构建单元。对所得的羟吲哚-β-内酰胺和羟吲哚-γ-内酰胺杂化物抑制相关中枢神经系统靶点(即胆碱酯酶和单胺氧化酶)的潜力进行了评估。还进行了类药性质评估,化合物 和 在低微摩尔范围内表现出作为选择性丁酰胆碱酯酶抑制剂的巨大潜力,具有有趣的预测药代动力学特征。我们在此报告的研究结果表明,羟吲哚-内酰胺杂化物是治疗阿尔茨海默病的新潜在药物。